Sexual Dysfunction

A prostate cancer vaccine and an infertility diagnostic tool are among the other pipeline products discussed in this round-up.

Shock wave therapy has now been subjected to multiple randomized, placebo-controlled, and additional open-label studies in clinics worldwide, demonstrating impressive efficacy and safety.

Experience with low-intensity extracorporeal shock wave therapy from multinational clinical trials demonstrates it is a safe, effective, and well-tolerated treatment for erectile dysfunction, including in men who do not respond to an oral phosphodiesterase type-5 inhibitor, reported Robert Feldman, MD, at the AUA annual meeting in New Orleans.

The association between testosterone replacement therapy (TRT) and thrombotic risk in elderly men remains controversial. While the FDA has mandated that all approved testosterone products include warnings about a possible increase in cardiovascular, stroke, and venous blood clot risk, at least one study presented at the AUA annual meeting in New Orleans found no link between TRT and cardiovascular events.

In this round-up of new urology products and services, learn about the FDA approving an oral agent for HSDD, an app that helps men with erectile dysfunction, and more.

In this installment of "Product Preview," also look for information on products in the pipeline for renal cell carcinoma and interstitial cystitis.

Here are the AUA 2015 take-home messages on sexual/dysfunction, presented by Landon Trost, MD.

Two recently published studies significantly contribute to current knowledge regarding testosterone therapy and cardiovascular health, says one expert urologist.

In this round-up of new urology products and services, learn about an app that helps moviegoers with OAB, a new mesh for sacrocolpopexy, and device/smartphone app that help women with pelvic floor exercises.

A novel investigational oral testosterone replacement therapy restored and maintained testosterone levels to a eugonadal range in 88% of hypogondal men treated with the agent in a randomized clinical trial.

Use of testosterone replacement therapy more than tripled between 2003 and 2012 in a population of reproductive-age men, according to a study presented at the AUA annual meeting in New Orleans.

“The FDA is being very cautious, which as the protector of public health, it’s got to be," says one urologist.

Urology Times’ “Best of AUA 2015” report provides a guide to the meeting’s take-home messages in 15 therapeutic areas-an information-packed, condensed summary of the top papers and presentations.

A study of more than 300 men sheds new light on the prostate safety of testosterone replacement therapy.

Other products featured include: Radiosurgery collimator allows treatment of broad rang of tumors and Phi prostate cancer test and more.

Most health information seekers navigate the Internet for what they think will be the best information available about their health condition or that of a loved one. Unfortunately, the Internet is unfiltered, unregulated, and often saturated with promotional, unsubstantiated, and at times frightening information.

Patients taking to the Internet for information about testosterone replacement therapy are likely getting an incomplete picture of the potential risks and adverse effects linked with the treatment, say researchers from Northwestern University Feinberg School of Medicine, Chicago, and the University of Pennsylvania, Philadelphia.

Products in the pipeline for prostate cancer, bladder cancer, and much more.

Other products featured include a spacer system to protect men undergoing PCa radiotherapy, a pelvic floor exercise app, and more.

A newly published review suggests that age-related testosterone deficiency treatment with intramuscular injections of testosterone replacement therapy offers health benefits and lower cardiovascular risk compared to testosterone replacement by patch or gel.

Products in the pipeline for prostate cancer, bladder cancer, stress urinary incontinence, chronic prostatitis/chronic pelvic pain syndrome, hypoactive sexual desire disorder.

To help you maximize your AUA experience, Urology Times’ editorial board and other thought leaders have pored over hundreds of abstracts to identify the key trends and can’t-miss research from this year’s meeting.

Other highly read UT articles this month include a large comparison of robotic and open RP, answers to your questions about coding for prostate biopsy, and several studies about risks for low and high T.

A new testosterone nasal gel (Natesto) is safe and efficacious, according to phase III data presented at the Endocrine Society annual meeting in San Diego.

A handful of new studies reveal new information about risk factors for both low and high testosterone as well as the potential risks associated with each.

The FDA acted on recommendations from one of its advisory committees by requiring manufacturers of testosterone therapies to make label changes that restrict the drugs’ usage.

In the experience of Martin Miner, MD, and Joel Heidelbaugh, MD, men’s health is far more than the working relationship between urology and primary care centered around male-specific medical concerns, and includes several different and significant subspecialties.

A literature review has found no evidence that testosterone therapy increases cardiovascular risk.

New products and services from Samsung Electronics America, Syneron Medical, American Medical Systems, New Star, Buffalo Filter, Cook Medical, Endo International, Trimel BioPharma Metamark, and the National Comprehensive Cancer Network.

The 2015 omnibus spending bill canceled a $10 million appropriation for the Independent Payment Advisory Board (IPAB). Congress also approved a bill that cuts Medicare funding for vacuum erection systems. Rationing care, whether undertaken by the IPAB or Congress, must be opposed when it arbitrarily selects services based on public perception and not medical necessity, writes Ross E. Weber of the AACU.